AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office.[2] AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days."[3] Its platform for single-cell screening was initially developed at the University of British Columbia.[4]
History
AbCellera was founded in 2012 by biomedical researchers Carl Hansen, Véronique Lecault, Kevin Heyries, Daniel Da Costa, Kathleen Lisaingo, and Oleh Petriv. In November 2016, the company received a US$645K grant from the Bill & Melinda Gates Foundation to develop a test for tuberculosis.[5]